The EGCA Group's most recent new venture is the EG Life-Sciences Fund I which it launched in May 2017. The fund invests in listed biotech companies developing gene and cell therapy technologies which are at the clinical testing stage. Our view is that by carefully selecting companies developing innovative treatments with significant commercial potential we can deliver venture capital-style returns with public market liquidity.
This is for informational purposes only.
EG Capital Advisors UK Limited advises the Group’s EG Life Sciences Fund which was the winner of this award.